Biotech stocks continued to surge on Wednesday after two scientists responsible for gene-editing tool CRISPR received this year’s Nobel Prize for Chemistry. CRISPR-powered stocks Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and Beam Therapeutics (BEAM) have now jumped 13%, 11%, and 6% respectively. CRISPR Therapeutics (CRSP), co-founded by one of the Nobel winners Emmanuelle Charpentier, is also up more than 11% since Wednesday morning. Collectively, these four CRISPR stocks are now worth nearly $12.2 billion — up from $6.5 billion in February with nearly $430 million added to their market values overnight. Now valued beyond $7.1 billion, CRSP is by far the biggest CRISPR-centric company…
This story continues at The Next Web
CRISPR’s Nobel Prize sent gene-editing stocks into overdrive
The Next Web
0 shares
1 views
You might like
Related news coverage
2 women scientists win Nobel in chemistry for genome editing
Two women scientists have been awarded the 2020 Nobel Prize in Chemistry for developing the tools to edit DNA, the Royal Swedish..
Mid-Day